Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aortic thrombosis24.01.09.0010.000091%Not Available
Application site dermatitis23.03.04.014; 12.07.01.018; 08.02.01.0180.000309%Not Available
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.0050.003399%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.001545%Not Available
Application site oedema12.07.01.020; 08.02.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.0040.003553%Not Available
Application site pruritus08.02.01.005; 23.03.12.004; 12.07.01.0050.001854%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.0160.005562%Not Available
Application site reaction12.07.01.006; 08.02.01.0060.002163%Not Available
Application site warmth12.07.01.029; 08.02.01.029--Not Available
Arrhythmia02.03.02.0010.000682%Not Available
Arterial thrombosis24.01.01.0020.000382%Not Available
Arteriosclerosis24.04.02.0010.000500%Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000818%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atelectasis22.01.02.0010.000091%
Atrial fibrillation02.03.03.0020.003808%
Atrial flutter02.03.03.0030.000273%
Atrophy08.03.04.001--Not Available
Azoospermia21.03.03.0010.001699%
Back pain15.03.04.005--
Benign prostatic hyperplasia21.04.02.0010.000445%Not Available
Blindness06.02.10.003; 17.17.01.0030.000454%Not Available
Blindness transient06.02.10.006; 17.17.01.0040.000091%Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.000273%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 19 Pages